A new treatment for Lyme arthritis using a specific protein inhibitor
A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor
This study is exploring a new treatment for Lyme arthritis that might help people who haven't found relief with regular antibiotics, using a special protein that could help fight the bacteria and ease their symptoms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | L2 Diagnostics, LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11008266 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic approach for Lyme arthritis, a condition that can arise from Lyme disease caused by the Borrelia burgdorferi bacteria. The study investigates the use of a human secretory leukocyte protease inhibitor (SLPI) that has shown potential in binding to the bacteria and may help alleviate symptoms associated with Lyme arthritis and Post Treatment Lyme Disease Syndrome (PTLDS). The approach aims to provide a more effective treatment option for patients who do not respond to standard antibiotic therapies. By targeting the underlying mechanisms of the disease, this research seeks to improve patient outcomes and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Lyme arthritis or those experiencing symptoms of PTLDS.
Not a fit: Patients who have not been diagnosed with Lyme disease or those whose symptoms are unrelated to Lyme arthritis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients suffering from Lyme arthritis and PTLDS.
How similar studies have performed: While there has been significant research on Lyme disease treatments, the specific use of SLPI as a therapeutic agent represents a novel approach that has not been extensively tested.
Where this research is happening
New Haven, United States
- L2 Diagnostics, LLC — New Haven, United States (Active)
Researchers
- Principal investigator: Fikrig, Erol — L2 Diagnostics, LLC
- Study coordinator: Fikrig, Erol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.